Dov Flex
YOU?
Author Swipe
View article: Supplementary Material for: Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial
Supplementary Material for: Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial Open
Background: The incidence of epidermal growth factor receptor inhibitor (EGFRI)-induced papulopustular rash is 60–85%. Objective: To investigate prophylactic topical treatment for EGFRI-induced rash. Methods: A single-center, randomized, d…
View article: Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity Open
We conclude that while NA treatment has no effect on operation complexity, peri-OP mortality or post-OP morbidity; its impact on long term survival is protuberant, therefore, we believe that NA treatment should be considered as the treatme…
View article: P13.10 Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases
P13.10 Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases Open
BACKGROUND: Central nervous system (CNS) metastases occur in about 30% of patients (pts) with advanced non-small cell lung cancer (NSCLC). Local treatment strategies (e.g., radiotherapy or surgery) result in delays in systemic therapy admi…